Insights

Innovative Aging Solutions Turn Biotechnologies specializes in cutting-edge epigenetic reprogramming therapies aimed at reversing aging processes, presenting opportunities to collaborate with longevity clinics, anti-aging treatment centers, and wellness platforms seeking advanced rejuvenation solutions.

Strategic Partnerships Recent partnerships with HanAll Biopharma for ophthalmic and otic disease therapies highlight the company's interest in expanding its portfolio, suggesting sales opportunities in ophthalmology, audiology, and related healthcare segments looking for regenerative treatment options.

Advanced Delivery Platforms The launch of eTurna, a novel nucleic acid delivery platform, opens doors to businesses involved in gene therapy, personalized medicine, and biotech R&D seeking innovative delivery mechanisms to enhance therapeutic efficacy.

Focus on Age-Related Diseases Turning aging-related indications into therapeutic products creates potential sales channels with hospitals, clinics, and research institutions dedicated to age-associated diseases such as macular degeneration and hearing loss, which are targeted in their current development pipeline.

Emerging Market Potential With a growing revenue range of up to 10 million dollars and recent expansions into epigenetic and regenerative therapies, Turn Biotechnologies presents a promising opportunity for investors and suppliers focused on innovative biotech startups targeting the aging population.

Turn Biotechnologies Tech Stack

Turn Biotechnologies uses 8 technology products and services including CIM Technologies, jQuery CDN, Open Graph, and more. Explore Turn Biotechnologies's tech stack below.

  • CIM Technologies
    Cad & Graphics
  • jQuery CDN
    Content Delivery Network
  • Open Graph
    Content Management System
  • Squarespace
    Content Management System
  • jQuery
    Javascript Libraries
  • SAP Maintenance, Repair, and Overhaul
    Operations
  • Google
    Search Engines
  • HSTS
    Security

Media & News

Turn Biotechnologies's Email Address Formats

Turn Biotechnologies uses at least 1 format(s):
Turn Biotechnologies Email FormatsExamplePercentage
First.Last@turn.bioJohn.Doe@turn.bio
49%
First.L@turn.bioJohn.D@turn.bio
1%
First.Last@turn.bioJohn.Doe@turn.bio
49%
First.L@turn.bioJohn.D@turn.bio
1%

Frequently Asked Questions

What is Turn Biotechnologies's official website and social media links?

Minus sign iconPlus sign icon
Turn Biotechnologies's official website is turn.bio and has social profiles on LinkedInCrunchbase.

What is Turn Biotechnologies's SIC code NAICS code?

Minus sign iconPlus sign icon
Turn Biotechnologies's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Turn Biotechnologies have currently?

Minus sign iconPlus sign icon
As of December 2025, Turn Biotechnologies has approximately 32 employees across 3 continents, including North AmericaAfricaEurope. Key team members include Chief Executive Officer: A. K.Co-Founder & Chief Operating Officer: S. R.Executive Board Member, Svp Global Corporate & Business Development: M. B.. Explore Turn Biotechnologies's employee directory with LeadIQ.

What industry does Turn Biotechnologies belong to?

Minus sign iconPlus sign icon
Turn Biotechnologies operates in the Biotechnology Research industry.

What technology does Turn Biotechnologies use?

Minus sign iconPlus sign icon
Turn Biotechnologies's tech stack includes CIM TechnologiesjQuery CDNOpen GraphSquarespacejQuerySAP Maintenance, Repair, and OverhaulGoogleHSTS.

What is Turn Biotechnologies's email format?

Minus sign iconPlus sign icon
Turn Biotechnologies's email format typically follows the pattern of First.Last@turn.bio. Find more Turn Biotechnologies email formats with LeadIQ.

When was Turn Biotechnologies founded?

Minus sign iconPlus sign icon
Turn Biotechnologies was founded in 2018.

Turn Biotechnologies

Biotechnology ResearchCalifornia, United States11-50 Employees

Aging has been called “the emperor of all maladies.” Turn Bio’s goal is to address multiple aging-related indications using a single powerful reprogramming therapy that turns old cells young again, aiding in the rejuvenation of an aged human body.

In 2013, a paper in Cell (The hallmarks of aging, López-Otin et al.,) proposed nine key “Hallmarks of Aging” that are causes of the general phenotype we refer to as “aging.” Our team recognized that it would be necessary to “turn back the clock” on each of these hallmarks and so set out to develop the technology to do just that. The task was achieved by a using a proprietary cocktail of transiently-administered rejuvenation factors that have now been shown to reverse eight of the nine hallmarks.

Join us as we embark on the task to "turn back time."

Section iconCompany Overview

Website
turn.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Turn Biotechnologies's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Turn Biotechnologies's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.